Kyowa Kirin receives European Commission approval for use of Crysvita (burosumab) for the treatment of tumour-induced osteomalacia

19 August 2022 - Crysvita is the first approved biologic treatment in the EU for patients with tumour-induced osteomalacia who cannot ...

Read more →

European Commission approves Celltrion Healthcare’s Vegzelma (CT-P16, biosimilar bevacizumab) for the treatment of multiple types of cancer

18 August 2022 - Vegzelma offers European patients living with certain types of breast, lung, renal, colon, rectum, ovarian and cervical ...

Read more →

Fresenius Kabi announces acceptance of its marketing authorisation application by the European Medicines Agency for MSB11456, a tocilizumab biosimilar candidate

18 August 2022 - Fresenius Kabi announced today that its marketing authorisation application for MSB11456, the company’s tocilizumab biosimilar candidate, ...

Read more →

European Commission approves Oncopeptides' Pepaxti for the treatment of patients with relapsed refractory multiple myeloma

18 August 2022 - Oncopeptides today announces that the European Commission has granted Pepaxti (melphalan flufenamide) marketing authorisation in combination ...

Read more →

Aeglea BioTherapeutics announces European Medicines Agency validation of marketing authorisation application for pegzilarginase for the treatment of arginase 1 deficiency

18 August 2022 - Aeglea BioTherapeutics today announced that a marketing authorisation application for pegzilarginase for the treatment of arginase 1 ...

Read more →

EMA starts review of conditional marketing authorisation application for Skycovion COVID-19 vaccine

18 August 2022 - The EMA’s CHMP has started a review of a conditional marketing authorisation application for Skycovion, a ...

Read more →

EMA publishes agenda for 16-19 August CHMP meeting

16 August 2022 - The EMA has published a draft agenda for this week's CHMP meeting. ...

Read more →

argenx announces European Commission approval of Vyvgart (efgartigimod alfa-fcab) for the treatment of generalised myasthenia gravis

11 August 2022 - Vyvgart is the first neonatal Fc receptor blocker approved in Europe for the treatment of adults living ...

Read more →

European Commission approves Imbruvica (ibrutinib) fixed duration combination for adult patients with previously untreated chronic lymphocytic leukaemia

9 August 2022 - It is the first all oral, fixed duration, once daily treatment based on a Bruton's tyrosine kinase ...

Read more →

EU regulator begins review of Pfizer-BioNTech's variant adapted COVID shot

9 August 2022 - The EMA has started a rolling review of a variant-adapted COVID-19 vaccine from Pfizer and BioNTech, ...

Read more →

Lynparza approved in the EU as adjuvant treatment for patients with germline BRCA mutated HER2 negative high-risk early breast cancer

4 August 2022 - First and only approved medicine targeting BRCA mutations in early breast cancer ...

Read more →

SK bioscience submits application for conditional marketing authorisation of COVID-19 vaccine, SKYCovion to European Medicines Agency

1 August 2022 - SK bioscience will accelerate to apply for emergency use listing to the World Health Organization. ...

Read more →

Pharming receives accelerated assessment in Europe for leniolisib for the treatment of rare immunodeficiency, APDS

1 August 2022 - Pharming is on track to submit its marketing authorisation application for leniolisib in H2 2022. ...

Read more →

Rinvoq (upadacitinib) approved by European Commission as an oral treatment for adults with active non-radiographic axial spondyloarthritis

29 July 2022 - Approval is supported by data from the Phase 3 SELECT-AXIS 2 pivotal clinical trial in which ...

Read more →

Big data use for public health: publication of Big Data Steering Group workplan 2022-25

28 July 2022 - The Big Data Steering Group set up by EMA and the Heads of Medicines Agencies has ...

Read more →